EAM
BCTXL

Empery Asset Management’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Empery Asset Management’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Hold
300,000
– – 0.31% 21
2026
Q1 		$309K Buy
+300,000
New +$318K 0.37% 18

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Empery Asset Management's BCTXL Position: Q2 2026 in Review

Empery Asset Management held its BriaCell Therapeutics Warrant (BCTXL) position steady in Q2 2026 at 300,000 shares worth $267K. The position accounts for 0.31% of the portfolio, ranked #21.

Empery Asset Management first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. The position peaked at $309K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Empery Asset Management held 300,000 shares of BriaCell Therapeutics Warrant worth $267K as of Q2 2026.
  • Empery Asset Management left its BriaCell Therapeutics Warrant share count unchanged in Q2 2026.
  • BriaCell Therapeutics Warrant made up 0.31% of Empery Asset Management's portfolio in Q2 2026, its #21 holding.
  • Empery Asset Management first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • Empery Asset Management's BriaCell Therapeutics Warrant position peaked at $309K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Empery Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.